Arama Sonuçları - Luis Paz‐Ares

Sonuçları Daraltın
  1. 1
    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain

    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain Yazar: Luis Paz-Ares, Luís Manso, Guillermo de Velasco

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    <i>KRAS</i>oncogene in lung cancer: focus on molecularly driven clinical trials

    <i>KRAS</i>oncogene in lung cancer: focus on molecularly driven clinical trials Yazar: Emmanuelle Kempf, Benoı̂t Rousseau, Benjamin Besse, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects Yazar: Solange Peters, Luis Paz‐Ares, Roy S. Herbst, Martin Reck

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Biological therapies in nonsmall cell lung cancer

    Biological therapies in nonsmall cell lung cancer Yazar: Jon Zugazagoitia, Sonia Molina‐Pinelo, Fernando López‐Ríos, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

    Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy Yazar: David P. Carbone, David R. Gandara, Scott Antonia, Christoph Zielinski, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

    Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors Yazar: David Westover, J. Zugazagoitia, Byoung Chul Cho, Christine M. Lovly, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

    Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Pati... Yazar: Jonathan W. Goldman, Peipei Shi, Martin Reck, Luis Paz‐Ares, Andrew Koustenis, Karla Hurt

    Baskı/Yayın Bilgisi 2015
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

    Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer Yazar: Bruce G. Robinson, Luis Paz‐Ares, Annetta Krebs, James R. Vasselli, Robert I. Haddad

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Current Challenges in Cancer Treatment

    Current Challenges in Cancer Treatment Yazar: Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  10. 10
    KRAS-Mutant non-small cell lung cancer: From biology to therapy

    KRAS-Mutant non-small cell lung cancer: From biology to therapy Yazar: Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William J. John, Luis Paz‐Ares, Gerald Schmid‐Bindert

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study

    Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study Yazar: Luis Paz‐Ares, Ádám Gondos, Diego Saldaña, Marlène Thomas, Céline Mascaux, Lukas Bubendorf, Fabrice Barlési

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis

    Clinical outcomes in non‐small‐cell lung cancer patients with <i>EGFR</i> mutations: pooled analysis Yazar: Luis Paz‐Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell, Barbara Klughammer

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Lung cancer: current therapies and new targeted treatments

    Lung cancer: current therapies and new targeted treatments Yazar: Fred R. Hirsch, Giorgio V. Scagliotti, James L. Mulshine, Regina Kwon, Walter J. Curran, Yi‐Long Wu, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim
    Revisão
    Favorilerime ekle
    Kaydedildi:
  14. 14
    Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

    Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study Yazar: Mustafa Özgüroğlu, Jonathan W. Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medić, Helen Mann, P. Chugh, Tapashi Dalvi, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2025
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  15. 15
    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer

    Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus... Yazar: Luis Paz‐Ares, Mark A. Socinski, Javad Shahidi, R.R. Hozak, Victoria Soldatenkova, Raffael Kurek, Marileila Varella‐Garcia, N. Thatcher, Fred R. Hirsch

    Baskı/Yayın Bilgisi 2016
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  16. 16
    ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Prior Platinum-Containing Line

    ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Pr... Yazar: Anna F. Farago, Benjamin J. Drapkin, Jose Antonio Lopez-Vilarino de Ramos, Carlos M. Galmarini, Rafael N. Nuñez, Carmen Kahatt, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  17. 17
    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up

    Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow... Yazar: Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Balázs Halmos, Marina Chiara Garassino, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz‐Ares

    Baskı/Yayın Bilgisi 2024
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  18. 18
    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials

    Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials Yazar: Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, José A. López-Martín, Luis Paz‐Ares, Guillermo de Velasco

    Baskı/Yayın Bilgisi 2018
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  19. 19
    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medi... Yazar: Pilar Garrido, Esther Conde, Javier de Castro, Javier Gómez‐Román, Enriqueta Felip, Lara Pijuán, Dolores Isla, Julián Sanz‐Ortega, Luis Paz‐Ares, Fernando López‐Ríos

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  20. 20
    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Med... Yazar: Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: